Litigation Details for INSULIN PRICING LITIGATION (D.N.J. 2023)

INSULIN PRICING LITIGATION (D.N.J. 2023)

Docket		Date Filed	2023-08-04
Court	District Court, D. New Jersey	Date Terminated
Cause	18:1962 Racketeering (RICO) Act	Assigned To	Brian R. Martinotti
Jury Demand	Plaintiff	Referred To	Leda Dunn Wettre
Patents	11,058,667; 11,135,192; 6,794,410; 8,114,833; 8,129,343; 8,318,800; 8,410,167; 8,536,122; 8,802,735; 9,107,900; 9,186,346; 9,302,009; 9,517,226; 9,937,143
Link to Docket	External link to docket

Details for INSULIN PRICING LITIGATION (D.N.J. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-08-04				External link to document
2023-08-04	200	Memorandum	covered by at least one patent: (1) Victoza: see, e.g., U.S. Patent No. 8,114,833; (2) Trulicity: see…, U.S. Patent Nos. 8,114,833; 8,129,343; 8,536,122; and (4) Soliqua: see, e.g., U.S. Patent Nos. RE45,313…the prices they charge on the patented medications. By creating the patent system, Congress has preempted…were covered by patents at the time the State filed the lawsuit and remain under patent,5 and Manufacturers… For patented products, Congress—not the states—is “the promulgator of patent policy.” Id.	External link to document
2023-08-04	277	Exhibit 7 - U.S. Patent No. 8,129,343	U.S. Patent No. 8,114,833, # 3 Exhibit 2 - U.S. Patent No. 7,452,966, # 4 Exhibit 3 - U.S. Patent No. ….S. Patent No. 10,709,766, # 6 Exhibit 5 - U.S. Patent No. 11,541,123, # 7 Exhibit 6 - U.S. Patent No.….S. Patent No. 8,129,343, # 9 Exhibit 8 - U.S. Patent No. 8,536,122, # 10 Exhibit 9 - U.S. Patent No. …, # 11 Exhibit 10 - U.S. Patent No. 9,526,764, # 12 Exhibit 11 - U.S. Patent No. 9,707,176)(CARROLL, BRIAN	External link to document

Insulin Pricing Litigation MDL 2:23-md-03080: Case Summary, Claims, Defendants and Commercial Risk

Last updated: August 24, 2026

The insulin pricing multidistrict litigation, In re Insulin Pricing Litigation, MDL No. 3080, No. 2:23-md-03080, consolidates federal claims alleging that insulin manufacturers and pharmacy benefit managers, or PBMs, used rebate arrangements, list-price increases and formulary incentives to inflate insulin prices and restrict competition. The principal manufacturer defendants are Eli Lilly, Novo Nordisk and Sanofi. The principal PBM defendants include entities associated with Express Scripts, CVS Caremark and OptumRx.

The case is pending in the U.S. District Court for the District of New Jersey before Judge Brian R. Martinotti. Publicly available procedural materials indicate that the litigation remains in the pretrial phase. The MDL does not primarily involve patent infringement, Orange Book litigation or Paragraph IV challenges. Its commercial significance is potential exposure to damages, injunctive relief, discovery burdens and changes to insulin contracting practices.

What is insulin pricing litigation MDL 2:23-md-03080?

MDL 2:23-md-03080 is a federal antitrust and consumer litigation proceeding concerning the pricing and distribution of insulin products in the United States.

The plaintiffs generally allege that:

• Insulin manufacturers raised or maintained high wholesale acquisition costs, commonly called list prices.
• Manufacturers paid rebates and other remuneration to PBMs and plan sponsors.
• PBM formulary systems favored products that generated larger rebates rather than products with the lowest net cost.
• The combined structure reduced competition and shifted costs to patients, employers, health plans and other payors.
• The defendants coordinated or participated in a common scheme affecting insulin pricing and market access.

The allegations remain unproven unless established through a judgment or settlement. The defendants have denied wrongdoing and have challenged the legal sufficiency and factual basis of the claims.

When was MDL 3080 created, and where is the case pending?

Item	Information
MDL number	3080
Civil action number	2:23-md-03080
Court	U.S. District Court for the District of New Jersey
Judicial officer	Judge Brian R. Martinotti
Subject	Insulin pricing, rebates, formulary placement and alleged anticompetitive conduct
Procedural posture	Consolidated federal pretrial proceedings
Centralization authority	Judicial Panel on Multidistrict Litigation
Primary legal theories	Antitrust, RICO, state consumer protection, unjust enrichment and related claims

The Judicial Panel on Multidistrict Litigation centralized related federal actions to promote coordinated discovery and pretrial rulings. MDL centralization does not resolve liability and does not itself create a class action.

The consolidated docket is distinct from individual state-court actions, government investigations and cases concerning insulin patents or biosimilar products.

Which companies are defendants in the insulin pricing litigation?

The litigation targets two principal groups: insulin manufacturers and PBMs.

Insulin manufacturers

The core manufacturer defendants are:

Company	Relevant insulin franchises
Eli Lilly and Company	Humalog, insulin lispro, Lyumjev and related products
Novo Nordisk Inc.	NovoLog, Fiasp, Levemir and related insulin products
Sanofi-Aventis U.S. LLC	Lantus, Toujeo, Apidra and related insulin products

The specific corporate entities named in a complaint can differ from the parent company names used commercially. Liability may depend on the role of each subsidiary, contracting entity and affiliate.

Pharmacy benefit managers

The principal PBM groups include:

PBM group	Commercial relationship
Express Scripts, Inc.	Cigna-related PBM operations
CVS Caremark	CVS Health-related PBM operations
OptumRx	UnitedHealth Group-related PBM operations
Prime Therapeutics and affiliated entities	PBM and health-plan services in certain markets

The claims against manufacturers and PBMs are not identical. Manufacturer claims focus on list prices, rebates and market conduct. PBM claims focus on formulary design, rebate negotiations, pass-through arrangements, spread pricing and alleged steering of utilization.

What legal claims are asserted in MDL 2:23-md-03080?

The pleadings generally rely on federal and state causes of action.

Sherman Act and antitrust claims

The central antitrust theory is that the defendants participated in an agreement or coordinated course of conduct that maintained elevated insulin prices and impaired competition.

Potential antitrust issues include:

• Whether the alleged conduct constitutes an agreement under Section 1 of the Sherman Act.
• Whether the relevant market is defined as insulin generally or narrower product markets, such as rapid-acting or basal insulin.
• Whether plaintiffs can establish antitrust injury and damages.
• Whether rebates were competition-enhancing discounts or exclusionary payments.
• Whether PBM formulary decisions reflect lawful purchasing negotiations or unlawful market allocation and foreclosure.

The market-definition issue will be important. Manufacturers may argue that insulin products compete across therapeutic classes and that patients, prescribers and payors have meaningful alternatives. Plaintiffs may argue that switching is limited by clinical, formulary and prescriber constraints.

RICO claims

Some complaints invoke the Racketeer Influenced and Corrupt Organizations Act. RICO claims generally require proof of an enterprise, a pattern of qualifying conduct, causation and injury to business or property.

RICO claims face pleading and proof requirements that can exceed ordinary consumer-protection claims. The alleged use of contracts, rebate data and communications may become central to whether plaintiffs can establish an enterprise and a pattern.

State consumer-protection and unfair-trade claims

State-law claims may allege that insulin prices, rebate practices or formulary representations were deceptive, unfair or misleading. These claims can create exposure across multiple jurisdictions, but they also raise questions concerning:

• State-by-state variations in statutory elements.
• Standing for indirect purchasers.
• Whether economic loss is recoverable.
• Whether federal law preempts claims involving ERISA plans or Medicare.
• Whether plaintiffs can prove reliance or causation.

Unjust enrichment and restitution

Plaintiffs may seek restitution based on alleged overpayments. Defendants are likely to contest whether unjust enrichment is available where plaintiffs purchased products indirectly, paid fixed copayments or were reimbursed by a health plan.

How strong are the plaintiffs’ claims against insulin manufacturers and PBMs?

The litigation presents material pleading and discovery risk, but liability is not established.

Factors supporting plaintiffs

Plaintiffs may rely on:

• Public evidence showing substantial historical increases in insulin list prices.
• The high concentration of major insulin supply among Lilly, Novo Nordisk and Sanofi.
• PBM rebate and formulary practices that can make higher-list-price products commercially attractive.
• Internal contracting documents and rebate data.
• Evidence that patients with deductibles or coinsurance may bear costs linked to list prices rather than net prices.
• Common market practices across the three principal insulin manufacturers.

Government reports have documented the complexity of insulin pricing and the role of manufacturers, wholesalers, PBMs, insurers and pharmacies in determining patient and plan costs. The Senate Finance Committee and other government bodies have examined insulin price increases and rebate structures, although those reports do not establish liability in MDL 3080. [1][2]

Factors supporting defendants

The defense is likely to emphasize:

• Price competition at the net-price level after rebates.
• The role of health plans and employers in formulary and benefit design.
• Differences between list prices, net prices, patient out-of-pocket costs and total plan spending.
• Independent commercial negotiations among manufacturers, PBMs and payors.
• The absence of a legal requirement that PBMs select the lowest list-price product.
• Clinical differences among insulin products.
• The inability of some plaintiffs to connect alleged conduct to individualized economic injury.
• Federal and ERISA-related limits on certain state-law claims.

The most consequential discovery will likely involve rebate contracts, formulary exclusions, market-share guarantees, administrative fees, price-protection clauses and communications concerning competing insulin products.

What is the litigation status of MDL 2:23-md-03080?

The case is in coordinated pretrial litigation rather than trial or final judgment.

Litigation stage	Status
Federal centralization	Completed
Coordinated pleadings	Ongoing through consolidated MDL procedures
Class certification	Not established by MDL creation
Merits discovery	Expected to focus on pricing, rebates, formularies and damages
Trial	No final trial judgment identified in the public procedural record used for this summary
Global settlement	No publicly reported global settlement identified through the stated record
Final liability ruling	None identified

MDL proceedings commonly move through several stages before trial:

1. Consolidation and appointment of leadership.
2. Consolidated pleadings and motions to dismiss.
3. Document production and depositions.
4. Expert analysis of market definition, pass-through economics and damages.
5. Class-certification motions.
6. Bellwether selection or representative trials.
7. Settlement negotiations or remand to originating courts.

A ruling on class certification would materially affect settlement leverage and potential damages. Certification is not automatic because purchasers may have experienced different prices, rebates, benefit designs, copayment structures and levels of insulin use.

Has the insulin pricing litigation settled?

No publicly reported global settlement for MDL 2:23-md-03080 is identified in the procedural record used for this analysis.

Manufacturer affordability programs, capped copayment initiatives and patient assistance changes are separate from a judicial settlement. Examples include manufacturer programs limiting monthly insulin copayments for eligible patients. Those commercial programs do not, by themselves, resolve antitrust or consumer claims.

A settlement would likely require analysis of:

• The class definition.
• Direct and indirect purchaser treatment.
• Cash-pay patients versus insured patients.
• Employer and health-plan claims.
• Monetary relief and claims administration.
• Prospective changes to rebate and formulary practices.
• Releases covering state and federal claims.
• Allocation among patients, plans and other payors.

What damages and commercial exposure could result?

The principal damages theory is overpayment. Plaintiffs may attempt to compare actual prices with a competitive benchmark absent the alleged conduct.

Potential damages models include:

• The difference between actual and but-for list prices.
• The difference between actual net prices and competitive net prices.
• Excess patient cost-sharing.
• Excess employer or health-plan spending.
• Restitution of alleged unlawful benefits.
• Treble damages under federal antitrust law, where available.
• Attorneys’ fees and injunctive relief.

The damages analysis is complicated by the distinction between:

• Wholesale acquisition cost.
• Manufacturer net price.
• PBM rebate amount.
• Pharmacy reimbursement.
• Patient copayment or coinsurance.
• Plan contribution.
• Government reimbursement.

Manufacturers face potential exposure tied to the scale of insulin utilization and historical price increases. PBMs face separate exposure tied to alleged retention or use of rebates, formulary exclusion practices and contractual compensation.

Does MDL 3080 involve Paragraph IV challenges or insulin patents?

No. MDL 2:23-md-03080 is a pricing and competition case, not a conventional Hatch-Waxman patent case.

Paragraph IV status

No Paragraph IV challenge is the central subject of the MDL. Paragraph IV litigation normally concerns an abbreviated new drug application alleging that a listed patent is invalid or not infringed. That framework does not determine whether insulin manufacturers or PBMs engaged in unlawful pricing conduct.

Orange Book status

The MDL is not an Orange Book patent-listing dispute. Individual insulin products may have patents or regulatory exclusivity issues, but those matters are separate from the consolidated pricing claims.

Biosimilar and follow-on insulin risk

Insulin competition can arise through:

• Biosimilar applications under the Public Health Service Act.
• Interchangeable biosimilar designations.
• Abbreviated new drug applications for products regulated under the Federal Food, Drug, and Cosmetic Act.
• Follow-on insulin products.
• Authorized generics or manufacturer-authorized alternatives.

Products such as insulin glargine and insulin lispro have faced follow-on competition, but entry barriers include manufacturing scale, device compatibility, pharmacy substitution rules, payer contracting and formulary access. Those barriers are commercially relevant to insulin pricing but do not convert MDL 3080 into a patent case.

How does insulin pricing litigation affect the competitive landscape?

The litigation increases pressure on the three leading insulin manufacturers and major PBMs to demonstrate that gross-price increases, rebates and formulary decisions produce legitimate competitive benefits.

Potential commercial effects include:

• Greater use of low-list-price insulin products.
• More direct discounts to patients.
• Reduced reliance on rebate-based formulary economics.
• Increased transparency obligations in contracts.
• Greater scrutiny of exclusionary formulary arrangements.
• Expansion of biosimilar and follow-on insulin competition.
• Increased payer demand for pass-through rebates.
• Additional state and federal enforcement activity.

The manufacturers’ 2023 decisions to reduce list prices or establish lower-priced insulin options may affect damages theories and future conduct, but those changes do not necessarily resolve historical claims. [3][4][5]

What generic entry risks exist for Lilly, Novo Nordisk and Sanofi?

Company	Primary risk	Commercial implication
Eli Lilly	Follow-on rapid-acting insulin and price-compression claims	Pressure on Humalog and related contracting economics
Novo Nordisk	Competition to NovoLog and basal insulin products	Risk to formulary share and rebate economics
Sanofi	Competition to Lantus and other insulin products	Greater pressure from biosimilar and follow-on glargine products
PBMs	Alleged retention or misuse of rebates	Potential damages, injunctions and contract restructuring

The greatest near-term risk is not necessarily a conventional generic launch. It is a combined pricing reset involving lower list prices, lower rebates, alternative benefit designs and greater availability of interchangeable or follow-on insulin.

What regulatory actions relate to insulin pricing?

The FDA regulates insulin approvals, biosimilars and interchangeability. It does not adjudicate the antitrust claims in MDL 3080.

The Federal Trade Commission has separately examined PBM business practices, including rebate arrangements, fees, formulary incentives and vertical integration. FTC scrutiny can increase litigation discovery risk and settlement pressure even when the agency’s investigation is separate from private MDL claims. [6]

Congressional investigations have also examined insulin pricing, the rebate system and patient out-of-pocket costs. These materials may be used by plaintiffs to frame market conduct, although they are not substitutes for proof under the antitrust statutes. [1][2]

Key Takeaways

• MDL 2:23-md-03080 is a federal insulin pricing and antitrust proceeding in the District of New Jersey.
• The principal manufacturer defendants are Eli Lilly, Novo Nordisk and Sanofi.
• Major PBM defendants include Express Scripts, CVS Caremark and OptumRx-related entities.
• The core allegations concern list prices, rebates, formulary placement and alleged coordination.
• The case is not primarily a patent, Orange Book or Paragraph IV dispute.
• No publicly reported global settlement is identified in the record used for this summary.
• The largest litigation variables are class certification, market definition, rebate economics and damages methodology.
• Follow-on insulin and biosimilar competition create separate commercial pressure and may influence settlement economics.
• Manufacturer affordability programs do not automatically resolve historical antitrust or consumer claims.

FAQs About Insulin Pricing Litigation MDL 2:23-md-03080

Is MDL 3080 a class action?

It is an MDL proceeding that consolidates related federal cases. Class treatment requires a separate court order under Federal Rule of Civil Procedure 23.

Can patients recover insulin overpayments?

Potential recovery depends on the final class definition, standing, proof of injury, applicable state law and any settlement or judgment.

Are PBMs accused of setting insulin prices?

The claims generally focus on PBM influence over rebates, formulary placement, reimbursement and benefit design rather than unilateral manufacturer list-price setting.

Do insulin patents block generic competition?

Some insulin products have patent, regulatory, device and manufacturing barriers, but MDL 3080 does not determine patent validity or infringement.

Could a settlement change insulin formularies?

Yes. A negotiated resolution could include prospective contracting, rebate-disclosure, formulary or patient-cost provisions, although no such settlement terms have been publicly established for MDL 3080.

References

1. U.S. Senate Committee on Finance. (2021). Insulin: Costs and access. U.S. Government Publishing Office.

2. U.S. House of Representatives, Committee on Energy and Commerce. (2021). Drug pricing investigation: Insulin pricing and the diabetes epidemic. U.S. House of Representatives.

3. Eli Lilly and Company. (2023, March 1). Lilly insulins now available for $35 per month for people with commercial insurance and people without insurance. https://www.lilly.com

4. Novo Nordisk. (2023, March 14). Novo Nordisk announces lower list prices for several insulin products. https://www.novonordisk.com

5. Sanofi. (2023, March 16). Sanofi to lower the price of Lantus and expand its patient support programs. https://www.sanofi.com

6. Federal Trade Commission. (2024). Pharmacy benefit managers: The powerful middlemen inflating drug costs and squeezing Main Street pharmacies. Federal Trade Commission.

7. Judicial Panel on Multidistrict Litigation. (2023). In re Insulin Pricing Litigation, MDL No. 3080, transfer and centralization proceedings. U.S. Judicial Panel on Multidistrict Litigation.

8. In re Insulin Pricing Litigation, No. 2:23-md-03080, U.S. District Court for the District of New Jersey. (2023-2024). Consolidated federal docket.